The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide multiple funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.
Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007. The Bristol-Myers Squibb/AstraZeneca diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.
An application may be made by a principal investigator and up to two co-investigators. All principal investigators must be paid-up EASD members
Research Grant Applications
Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review. The deadline for receipt of research grant applications for funding this year 15 January 2013.
Research grants for the purposes of this Programme are up to Euro 200,000. All budgets are to be prepared in Euro. For countries in which the Euro is not yet the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under "Budget Justification".
Programme and Research Focus
EFSD has established this new European Diabetes Research Programme in Patient Education to encourage new projects aimed at advancing current knowledge in this domain. To achieve the goals and objectives of this Programme, EFSD invite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis. The EFSD European Diabetes Research Programme in Patient Education will support research into the clinical and medical evaluation of the following:
•patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management;
• the potential impact of educational and disease management programmes focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease;
•efficacy of patient education in overcoming psychosocial challenges in type 2 diabetes.
Definition of Patient Education
Patient education has an impact in several areas of long-term patient management. Patient education increases patients' understanding of diabetes, it can prevent or delay complications and reduce the number and duration of hospitalisations, which in turn can improve quality of life and glycaemic outcome. Different methods of teaching people self-management practices and providing appropriate support may improve the effectiveness of diabetes self-management in the long term, with substantial potential benefit not only on quality of life, but also on health care costs.
Mechanism of Support and Review
Research will be supported through the award of grants, each of up to Euro 200,000. The duration of each award may be one year or longer, depending upon the needs of the project and as justified in the application. The Programme Board, at the suggestion of the Review Committee, may at its discretion recommend an award in a lin a different amount from that requested, but which is considered more appropriate for the proposed studies.
Applications for an EFSD research grant are invited from single non-profit institutions or groups of such institutions from Europe and associated countries. The principal investigator and any co-investigators must be employed full-time at a non-profit institution and the study must be performed at their place of work.
Applications will be subject to scientific review by a specialised ad hoc committee. Funding will require approval by an EFSD Board convened for this purpose. Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, EFSD reserves the right to request revision to applications in accordance with the recommendations of the Review Committee.
It is anticipated that applications will be received, reviewed and approved for funding by April 2013.
Deadline for Applications: 15 January 2013
Important! Please send your application as one complete PDF email attachment by 12:00 noon on the deadline date
Cal comunicar abans del 1 de desembre de 2012 que es vol participar a la convocatòria, enviant un e-mail a convocatories@iispv.cat . Termini IISPV 21 12 2012
Work
C/ Dr. Mallafrè Guasch, 4
Edifici modular Hospital Universitari de Tarragona Joan XXIII
43007 Tarragona
Tel./Fax Work977 24 97 72 http://www.iispv.cathttp://www.iispv.cat
Work
C/ Sant Llorenç, 21
Planta baixa de l'edifici 4 de la Facultat de Medicina i Ciències de la Salut
43201 Reus (Tarragona)
Tel./Fax Work977 75 93 96 / 977 75 93 95
Fax977 75 93 93
http://www.iispv.cathttp://www.iispv.cat